Selective MC2R Antagonists for Glucocorticoid Excess Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions like Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, congenital adrenal hyperplasia, depressive illness, and septic shock often have significant side effects due to the non-specific modulation of melanocortin receptors, particularly MC2R, which are not adequately addressed by existing therapies.
Innovation Solution
Development of selective MC2R antagonists that modulate the activity of the melanocortin subtype-2 receptor (MC2R) to treat these conditions, reducing unwanted side effects by specifically targeting ACTH-mediated glucocorticoid excess.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific modulation of melanocortin receptors is used to treat conditions like Cushing's syndrome, then therapeutic effect is achieved, but significant side effects occur
Solution Approach 1:
The patent applies local quality by developing MC2R-selective antagonists that provide targeted modulation specific to the MC2R receptor subtype. This selectivity allows therapeutic effect on glucocorticoid excess while minimizing off-target effects on other melanocortin receptors (MC1R, MC3R, MC4R, MC5R), thereby reducing side effects while maintaining therapeutic reliability.
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical structure of melanocortin receptor modulators to achieve MC2R selectivity. Through structural optimization (changing molecular parameters), the compounds exhibit high affinity and specificity for MC2R, enabling differentiated pharmacological activity that targets the therapeutic indication while avoiding harmful effects on other receptor subtypes.
2Adaptability or versatility
If existing therapies modulate melanocortin receptors, then conditions like Cushing's disease are treated, but side effects are not adequately addressed
Solution Approach 1:
The patent applies segmentation by dividing the melanocortin receptor family into distinct subtypes (MC1R, MC2R, MC3R, MC4R, MC5R) and developing selective antagonists for specific subtypes. This segmentation approach allows tailored therapy for MC2R-mediated conditions like Cushing's syndrome while avoiding activation of other receptor subtypes that cause side effects, thus improving treatment coverage with reduced harm.
Solution Approach 2:
The patent employs intermediary principles by introducing MC2R-selective antagonists as mediating substances that specifically block ACTH signaling at the MC2R receptor. These selective antagonists act as intermediaries that prevent harmful downstream effects while preserving beneficial therapeutic actions, thereby addressing side effects without compromising treatment effectiveness.
3Object-affected harmful factors
If selective MC2R antagonists are developed, then side effects are reduced, but drug development complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the chemical structure of MC2R antagonists through medicinal chemistry. By modifying molecular parameters (substituents, functional groups, stereochemistry), the compounds achieve high selectivity for MC2R over other melanocortin receptors, reducing side effects while maintaining manageable development complexity through structured chemical modification approaches.
Data Source
AI summary
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.